Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H McCabe

Showing results (161-170 of 259) with videos related to

Pageof 26
Sort By:
European Journal of Neurology|September 22, 2012
High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) studyW O Tobin, J A Kinsella, T Coughlan, et al.
Journal of the American College of Cardiology|March 1, 1987
Incidence and management of limb ischemia with percutaneous wire-guided intraaortic balloon cathetersJ D Alderman, G I Gabliani, C H McCabe, et al.
The New England Journal of Medicine|March 10, 2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromesChristopher P Cannon, Eugene Braunwald, Carolyn H McCabe, et al.
The New England Journal of Medicine|October 31, 1996
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromesE M Antman, M J Tanasijevic, B Thompson, et al.
Clinical Chemistry|August 25, 2007
Clinical application of C-reactive protein across the spectrum of acute coronary syndromesBenjamin M Scirica, David A Morrow, Christopher P Cannon, et al.
JAMA|September 7, 2005
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY studyMarc S Sabatine, Christopher P Cannon, C Michael Gibson, et al.
American Heart Journal|April 30, 1999
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 InvestigatorsF Van de Werf, C P Cannon, A Luyten, et al.
Journal of the American College of Cardiology|December 1, 1994
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC P Cannon, C H McCabe, D J Diver, et al.
American Heart Journal|October 12, 2010
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)Christian T Ruff, Robert P Giugliano, Elliott M Antman, et al.
The American Journal of Cardiology|May 27, 2006
Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trialSatish Bhadriraju, Kausik K Ray, Anthony C DeFranco, et al.
Pageof 26

Showing results (161-170 of 259) with videos related to

Sort By:
Pageof 26
European Journal of Neurology|September 22, 2012
High on-treatment platelet reactivity on commonly prescribed antiplatelet agents following transient ischaemic attack or ischaemic stroke: results from the Trinity Antiplatelet Responsiveness (TRAP) studyW O Tobin, J A Kinsella, T Coughlan, et al.
Journal of the American College of Cardiology|March 1, 1987
Incidence and management of limb ischemia with percutaneous wire-guided intraaortic balloon cathetersJ D Alderman, G I Gabliani, C H McCabe, et al.
The New England Journal of Medicine|March 10, 2004
Intensive versus moderate lipid lowering with statins after acute coronary syndromesChristopher P Cannon, Eugene Braunwald, Carolyn H McCabe, et al.
The New England Journal of Medicine|October 31, 1996
Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromesE M Antman, M J Tanasijevic, B Thompson, et al.
Clinical Chemistry|August 25, 2007
Clinical application of C-reactive protein across the spectrum of acute coronary syndromesBenjamin M Scirica, David A Morrow, Christopher P Cannon, et al.
JAMA|September 7, 2005
Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY studyMarc S Sabatine, Christopher P Cannon, C Michael Gibson, et al.
American Heart Journal|April 30, 1999
Safety assessment of single-bolus administration of TNK tissue-plasminogen activator in acute myocardial infarction: the ASSENT-1 trial. The ASSENT-1 InvestigatorsF Van de Werf, C P Cannon, A Luyten, et al.
Journal of the American College of Cardiology|December 1, 1994
Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trialC P Cannon, C H McCabe, D J Diver, et al.
American Heart Journal|October 12, 2010
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)Christian T Ruff, Robert P Giugliano, Elliott M Antman, et al.
The American Journal of Cardiology|May 27, 2006
Association between blood glucose and long-term mortality in patients with acute coronary syndromes in the OPUS-TIMI 16 trialSatish Bhadriraju, Kausik K Ray, Anthony C DeFranco, et al.
Pageof 26